These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15934856)

  • 1. The cerebrovascular risks associated with tamoxifen use.
    Bushnell C
    Expert Opin Drug Saf; 2005 May; 4(3):501-7. PubMed ID: 15934856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroke risk and tamoxifen therapy for breast cancer.
    Geiger AM; Fischberg GM; Chen W; Bernstein L
    J Natl Cancer Inst; 2004 Oct; 96(20):1528-36. PubMed ID: 15494603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study.
    Hernandez RK; Sørensen HT; Pedersen L; Jacobsen J; Lash TL
    Cancer; 2009 Oct; 115(19):4442-9. PubMed ID: 19569248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
    Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
    J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
    Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
    J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen treatment and new-onset depression in breast cancer patients.
    Lee KC; Ray GT; Hunkeler EM; Finley PR
    Psychosomatics; 2007; 48(3):205-10. PubMed ID: 17478588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
    Dunn BK; Ford LG
    Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
    Johansen J; Overgaard J; Overgaard M
    Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention of breast cancer for women at high risk.
    Chan K; Morris GJ
    Semin Oncol; 2006 Dec; 33(6):642-6. PubMed ID: 17145342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen: an enduring star.
    Veronesi U; Maisonneuve P; Decensi A
    J Natl Cancer Inst; 2007 Feb; 99(4):258-60. PubMed ID: 17312297
    [No Abstract]   [Full Text] [Related]  

  • 16. Tamoxifen treatment in Danish breast cancer patients and 5-year risk of arterial atherosclerotic events: a null association.
    Hernandez RK; Sørensen HT; Jacobsen J; Pedersen L; Lash TL
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2509-11. PubMed ID: 18768523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence of stroke with tamoxifen in NSABP B-24.
    Dignam JJ; Fisher B
    Lancet; 2000 Mar; 355(9206):848-9. PubMed ID: 10711957
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
    Gligorov J; Pritchard K; Goss P
    Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stopping tamoxifen peri-operatively for VTE risk reduction: a proposed management algorithm.
    Hussain T; Kneeshaw PJ
    Int J Surg; 2012; 10(6):313-6. PubMed ID: 22609485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.